JP2019535275A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535275A5 JP2019535275A5 JP2019526305A JP2019526305A JP2019535275A5 JP 2019535275 A5 JP2019535275 A5 JP 2019535275A5 JP 2019526305 A JP2019526305 A JP 2019526305A JP 2019526305 A JP2019526305 A JP 2019526305A JP 2019535275 A5 JP2019535275 A5 JP 2019535275A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- domain
- signal transduction
- item
- intracellular signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 459
- 229920001184 polypeptide Polymers 0.000 claims description 407
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 407
- 230000004927 fusion Effects 0.000 claims description 125
- 230000031146 intracellular signal transduction Effects 0.000 claims description 122
- 230000004068 intracellular signaling Effects 0.000 claims description 69
- 241000700605 Viruses Species 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 44
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 claims description 16
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 claims description 16
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 claims description 16
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 102100039340 Interleukin-18 receptor 1 Human genes 0.000 claims description 11
- 101710184759 Interleukin-18 receptor 1 Proteins 0.000 claims description 11
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 claims description 11
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 claims description 11
- 102000006306 Antigen Receptors Human genes 0.000 claims description 8
- 108010083359 Antigen Receptors Proteins 0.000 claims description 8
- -1 CD44v7 / 8 Proteins 0.000 claims description 8
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 6
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims description 6
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 claims description 6
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 238000003776 cleavage reaction Methods 0.000 claims description 6
- 102000003675 cytokine receptors Human genes 0.000 claims description 6
- 108010057085 cytokine receptors Proteins 0.000 claims description 6
- 230000007017 scission Effects 0.000 claims description 5
- 241000214054 Equine rhinitis A virus Species 0.000 claims description 4
- 102000010956 Glypican Human genes 0.000 claims description 4
- 108050001154 Glypican Proteins 0.000 claims description 4
- 108050007237 Glypican-3 Proteins 0.000 claims description 4
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 201000002491 encephalomyelitis Diseases 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 102000002689 Toll-like receptor Human genes 0.000 claims description 3
- 108020000411 Toll-like receptor Proteins 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 102000027596 immune receptors Human genes 0.000 claims description 3
- 108091008915 immune receptors Proteins 0.000 claims description 3
- 108010093036 interleukin receptors Proteins 0.000 claims description 3
- 102000002467 interleukin receptors Human genes 0.000 claims description 3
- 102000007863 pattern recognition receptors Human genes 0.000 claims description 3
- 108010089193 pattern recognition receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 2
- 108700012439 CA9 Proteins 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims description 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 102000012804 EPCAM Human genes 0.000 claims description 2
- 101150084967 EPCAM gene Proteins 0.000 claims description 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 2
- 101710088083 Glomulin Proteins 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 2
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 2
- 102000036673 PRAME Human genes 0.000 claims description 2
- 108060006580 PRAME Proteins 0.000 claims description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 2
- 102100037686 Protein SSX2 Human genes 0.000 claims description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 2
- 108010002687 Survivin Proteins 0.000 claims description 2
- 102100035721 Syndecan-1 Human genes 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 2
- 241001420369 Thosea Species 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 230000001605 fetal effect Effects 0.000 claims description 2
- 102000006815 folate receptor Human genes 0.000 claims description 2
- 108020005243 folate receptor Proteins 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 239000012642 immune effector Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000007030 peptide scission Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 101150047061 tag-72 gene Proteins 0.000 claims description 2
- 108010071260 virus protein 2A Proteins 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 description 12
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 description 8
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 description 8
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 8
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 8
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 8
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 8
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 8
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 8
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 8
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 8
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 8
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 description 8
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 description 8
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 8
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 8
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 8
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 8
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 8
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 8
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 8
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 8
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 8
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 8
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023064901A JP7627399B2 (ja) | 2016-11-17 | 2023-04-12 | ＴＧＦβシグナルコンバーター |
| JP2024219730A JP2025061659A (ja) | 2016-11-17 | 2024-12-16 | ＴＧＦβシグナルコンバーター |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662423565P | 2016-11-17 | 2016-11-17 | |
| US62/423,565 | 2016-11-17 | ||
| US201762467496P | 2017-03-06 | 2017-03-06 | |
| US62/467,496 | 2017-03-06 | ||
| PCT/US2017/062358 WO2018094244A1 (en) | 2016-11-17 | 2017-11-17 | TGFβ SIGNAL CONVERTOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064901A Division JP7627399B2 (ja) | 2016-11-17 | 2023-04-12 | ＴＧＦβシグナルコンバーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535275A JP2019535275A (ja) | 2019-12-12 |
| JP2019535275A5 true JP2019535275A5 (enExample) | 2020-12-24 |
| JP7263235B2 JP7263235B2 (ja) | 2023-04-24 |
Family
ID=62145775
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019526305A Active JP7263235B2 (ja) | 2016-11-17 | 2017-11-17 | ＴＧＦβシグナルコンバーター |
| JP2023064901A Active JP7627399B2 (ja) | 2016-11-17 | 2023-04-12 | ＴＧＦβシグナルコンバーター |
| JP2024219730A Pending JP2025061659A (ja) | 2016-11-17 | 2024-12-16 | ＴＧＦβシグナルコンバーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023064901A Active JP7627399B2 (ja) | 2016-11-17 | 2023-04-12 | ＴＧＦβシグナルコンバーター |
| JP2024219730A Pending JP2025061659A (ja) | 2016-11-17 | 2024-12-16 | ＴＧＦβシグナルコンバーター |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11654158B2 (enExample) |
| EP (2) | EP4353822A3 (enExample) |
| JP (3) | JP7263235B2 (enExample) |
| KR (2) | KR102653324B1 (enExample) |
| CN (2) | CN110072885B (enExample) |
| AU (3) | AU2017362484B2 (enExample) |
| BR (1) | BR112019009904A2 (enExample) |
| CA (1) | CA3043888A1 (enExample) |
| DK (1) | DK3541833T5 (enExample) |
| ES (1) | ES2977435T3 (enExample) |
| IL (2) | IL266628B2 (enExample) |
| MA (1) | MA46862A (enExample) |
| MX (2) | MX2019005724A (enExample) |
| WO (1) | WO2018094244A1 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
| US9725710B2 (en) | 2014-01-08 | 2017-08-08 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| CN108137669B (zh) * | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
| US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
| US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
| BR112019009904A2 (pt) | 2016-11-17 | 2019-08-13 | Bluebird Bio, Inc. | conversor de sinal de tgfss |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| KR20200110326A (ko) * | 2017-12-14 | 2020-09-23 | 블루버드 바이오, 인코포레이티드. | Daric 인터류킨 수용체 |
| KR20220066413A (ko) | 2017-12-14 | 2022-05-24 | 프로디자인 소닉스, 인크. | 음향 트랜스듀서 구동기 및 제어기 |
| AR114273A1 (es) | 2018-03-02 | 2020-08-12 | Allogene Therapeutics Inc | Receptores inducibles de citoquina quimérica |
| CN110615843B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
| CN113272318A (zh) * | 2018-09-05 | 2021-08-17 | 孔锡卿 | 用于实体癌的嵌合抗原受体和表达嵌合抗原受体的t细胞 |
| PH12021551861A1 (en) | 2019-03-01 | 2022-05-30 | Allogene Therapeutics Inc | Constitutively active chimeric cytokine receptors |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CN114375301B (zh) * | 2019-05-08 | 2025-08-05 | 基因医疗免疫疗法有限责任公司 | 工程改造的t细胞 |
| BR112022003553A2 (pt) * | 2019-08-30 | 2022-05-24 | Allogene Therapeutics Inc | Receptores de citocina quiméricos compreendendo domínios de ligação a tgf beta |
| WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
| KR20220079847A (ko) * | 2019-09-11 | 2022-06-14 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 키메라 직교성 수용체 단백질 및 사용 방법 |
| US20240083974A1 (en) * | 2019-10-15 | 2024-03-14 | ETH Zürich | Artificial Transmembrane Proteins for Detecting Intracellular or Intravesicular Biomolecular Interactions |
| KR20210103975A (ko) * | 2020-02-14 | 2021-08-24 | (주)이뮤노텍바이오팜코리아 | 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도 |
| CN115175929A (zh) | 2020-02-24 | 2022-10-11 | 艾洛基治疗公司 | 活性增强的bcma car-t细胞 |
| WO2022016119A1 (en) * | 2020-07-17 | 2022-01-20 | Simurx, Inc. | Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods |
| GB202012181D0 (en) * | 2020-08-05 | 2020-09-16 | Autolus Ltd | Chimeric receptor |
| WO2022037562A1 (en) * | 2020-08-17 | 2022-02-24 | Nanjing Legend Biotech Co., Ltd. | Engineered immunoresponsive cells and uses thereof |
| CN112194728B (zh) * | 2020-09-22 | 2023-07-11 | 沣潮医药科技（上海）有限公司 | 用于内毒素清除的嵌合抗原受体及其应用 |
| EP4232566A1 (en) * | 2020-10-22 | 2023-08-30 | Lyell Immunopharma, Inc. | Chimeric activation receptors |
| CN117157329A (zh) * | 2021-04-15 | 2023-12-01 | 南京传奇生物科技有限公司 | 融合蛋白及其用途 |
| TW202317602A (zh) * | 2021-07-15 | 2023-05-01 | 福瑞德哈金森腫瘤中心 | 嵌合多肽 |
| CN113698493B (zh) * | 2021-08-09 | 2022-05-31 | 北京东方百泰生物科技股份有限公司 | 一种针对VEGF和TGF-β的双功能蛋白及其应用 |
| EP4392463A4 (en) * | 2021-08-18 | 2025-09-17 | Legend Biotech Ireland Ltd | MODIFIED IMMUNE CELLS EXPRESSING TLR RECEPTORS |
| TW202328173A (zh) * | 2021-09-02 | 2023-07-16 | 大陸商廣東菲鵬製藥股份有限公司 中國廣東省東莞市松山湖園區桃園路1號10棟301室 郵編：523808 | TGFβRII突變體及其應用 |
| CN115873802A (zh) * | 2021-09-29 | 2023-03-31 | 亘喜生物科技（上海）有限公司 | 嵌合抗原受体免疫细胞及其制法和应用 |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| WO2023159162A2 (en) * | 2022-02-18 | 2023-08-24 | The Regents Of The University Of California | Improved primary human nk cell expansion and function by chimeric cytokine receptor |
| CN114539429B (zh) * | 2022-03-24 | 2022-07-29 | 上海普铭生物科技有限公司 | 融合蛋白组合物及其应用 |
| IL316137A (en) | 2022-04-08 | 2024-12-01 | Regeneron Pharma | Multipartite receptor and signaling complex |
| JP2025520227A (ja) | 2022-05-26 | 2025-07-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | レンチウイルスベクターを維持するための組成物及びその使用 |
| GB202301421D0 (en) * | 2023-02-01 | 2023-03-15 | Univ Oslo Hf | Switch receptor for use in adoptive cell therapy |
| CN118109416B (zh) * | 2023-03-30 | 2024-11-22 | 广州百吉生物制药有限公司 | 功能增强型工程化免疫细胞及其制备和应用 |
| WO2024254279A2 (en) * | 2023-06-06 | 2024-12-12 | The Johns Hopkins University | Velocity receptor expressing immune cells and uses thereof |
| WO2025064779A1 (en) * | 2023-09-20 | 2025-03-27 | University Of Southern California | Synthetic tgf-beta redirectors and uses thereof in chimeric antigen receptor-mediated cell therapy and others |
| WO2025194364A1 (en) * | 2024-03-20 | 2025-09-25 | Hangzhou Hervor Therapeutics Co., Ltd | ENGINEERED TGFβ RECEPTOR REPURPOSED FOR IL-9 SIGNALING AND USES THEREOF IN IMMUNE CELLS |
| CN119409837B (zh) * | 2024-10-31 | 2025-09-19 | 青岛瑞思德生物科技有限公司 | 一种用于巨噬细胞的嵌合转换型受体及其应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| EP0552178B1 (en) | 1990-10-12 | 1997-01-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Modified ribozymes |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US6838254B1 (en) | 1993-04-29 | 2005-01-04 | Conopco, Inc. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1999006583A1 (en) | 1997-07-31 | 1999-02-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| ES2302726T3 (es) | 2000-02-24 | 2008-08-01 | Invitrogen Corporation | Estimulacion y concentracion simultanea de celulas. |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
| ES2505700T3 (es) | 2000-06-01 | 2014-10-10 | University Of North Carolina At Chapel Hill | Vectores de parvovirus duplicados |
| AU2002257420A1 (en) | 2001-05-01 | 2002-11-11 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| AU2005316476A1 (en) | 2004-12-15 | 2006-06-22 | University Of Florida Research Foundation, Inc. | Chimeric vectors |
| EP1783228A1 (en) * | 2005-11-08 | 2007-05-09 | ETH Zürich | Recombinant expression of multiprotein complexes using polygenes |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| WO2011088081A1 (en) | 2010-01-12 | 2011-07-21 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| JP6141021B2 (ja) | 2010-02-05 | 2017-06-07 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | パルボウイルスの形質導入を増強するための組成物および方法 |
| CA2804280A1 (en) * | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
| MX347656B (es) | 2011-04-08 | 2017-05-08 | Baylor College Medicine | Inversion de los efectos del micro-ambiente de tumor utilizando receptores de citocina quimericos. |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| EP2986636B1 (en) | 2013-04-17 | 2018-11-14 | Baylor College Of Medicine | Immunosuppressive tgf-beta signal converter |
| DK3027204T3 (da) | 2013-07-29 | 2022-04-19 | 2Seventy Bio Inc | Flerdelte signaleringsproteiner og anvendelser deraf |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| JP6352215B2 (ja) | 2014-07-10 | 2018-07-04 | 株式会社デンソー | ガスセンサ素子 |
| JP7170394B2 (ja) * | 2015-01-31 | 2022-11-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 治療用分子のｔ細胞送達のための組成物および方法 |
| BR112017021510A2 (pt) * | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
| CA2938473A1 (en) | 2015-08-04 | 2017-02-04 | Fiberbuilt Manufacturing Inc. | Golf practice device |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| JP6699423B2 (ja) | 2016-07-21 | 2020-05-27 | コニカミノルタ株式会社 | 定着装置および画像形成装置 |
| BR112019009904A2 (pt) | 2016-11-17 | 2019-08-13 | Bluebird Bio, Inc. | conversor de sinal de tgfss |
| EP3714941A1 (en) | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| CN114375301B (zh) | 2019-05-08 | 2025-08-05 | 基因医疗免疫疗法有限责任公司 | 工程改造的t细胞 |
-
2017
- 2017-11-17 BR BR112019009904-2A patent/BR112019009904A2/pt unknown
- 2017-11-17 MX MX2019005724A patent/MX2019005724A/es unknown
- 2017-11-17 US US16/348,450 patent/US11654158B2/en active Active
- 2017-11-17 KR KR1020197017172A patent/KR102653324B1/ko active Active
- 2017-11-17 CN CN201780077533.1A patent/CN110072885B/zh active Active
- 2017-11-17 WO PCT/US2017/062358 patent/WO2018094244A1/en not_active Ceased
- 2017-11-17 DK DK17872043.9T patent/DK3541833T5/da active
- 2017-11-17 IL IL266628A patent/IL266628B2/en unknown
- 2017-11-17 CN CN202311619803.0A patent/CN117720665A/zh active Pending
- 2017-11-17 JP JP2019526305A patent/JP7263235B2/ja active Active
- 2017-11-17 ES ES17872043T patent/ES2977435T3/es active Active
- 2017-11-17 IL IL309526A patent/IL309526B2/en unknown
- 2017-11-17 CA CA3043888A patent/CA3043888A1/en active Pending
- 2017-11-17 EP EP23216595.1A patent/EP4353822A3/en active Pending
- 2017-11-17 MA MA046862A patent/MA46862A/fr unknown
- 2017-11-17 AU AU2017362484A patent/AU2017362484B2/en active Active
- 2017-11-17 EP EP17872043.9A patent/EP3541833B1/en active Active
- 2017-11-17 KR KR1020247010309A patent/KR20240046620A/ko active Pending
-
2019
- 2019-05-16 MX MX2024006758A patent/MX2024006758A/es unknown
-
2022
- 2022-03-15 AU AU2022201775A patent/AU2022201775B2/en active Active
-
2023
- 2023-04-07 US US18/297,491 patent/US12365711B2/en active Active
- 2023-04-12 JP JP2023064901A patent/JP7627399B2/ja active Active
-
2024
- 2024-05-29 AU AU2024203604A patent/AU2024203604A1/en active Pending
- 2024-12-16 JP JP2024219730A patent/JP2025061659A/ja active Pending
-
2025
- 2025-06-18 US US19/241,913 patent/US20250368956A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535275A5 (enExample) | ||
| IL309526B1 (en) | TGFBeta SIGNAL CONVERTOR | |
| US11382954B2 (en) | Binding proteins specific for RAS neoantigens and uses thereof | |
| Bai et al. | Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade | |
| JP2017536812A5 (enExample) | ||
| CN107326014B (zh) | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 | |
| US20230248768A1 (en) | Engineered immune cell for allotransplantation | |
| JP2019513347A5 (enExample) | ||
| CN116063550A (zh) | 靶向nk激活性受体的嵌合抗原受体 | |
| JP2017506513A5 (enExample) | ||
| Reindl et al. | Immunotherapy with NK cells: recent developments in gene modification open up new avenues | |
| HRP20200978T1 (hr) | Poboljšani postupci terapije proizvodnjom adoptivnih stanica | |
| JP2018518974A5 (enExample) | ||
| BR112021003031A2 (pt) | imunoterapia direcionada a antígenos kras ou her2 | |
| JP2023545907A (ja) | 新規共刺激ドメインを含むキメラ抗原受容体及びその使用 | |
| RU2020122708A (ru) | Рецепторы nkg2d daric | |
| JPWO2020227483A5 (enExample) | ||
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| Hu et al. | Application of adoptive cell therapy in malignant melanoma | |
| JPWO2021030149A5 (enExample) | ||
| WO2023207390A1 (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
| AU2019377553A1 (en) | T cell receptors specific for mesothelin and their use in immunotherapy | |
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| CN121127596A (zh) | 耐免疫排斥的工程化细胞 | |
| JPWO2021211948A5 (enExample) |